Trial Profile
Phase Ia Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Recombinant Humanized Anti-CD20 Monoclonal Antibody for Injection(B001)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Nov 2021
Price :
$35
*
At a glance
- Drugs B 001 (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Shanghai Pharmaceuticals Holding
- 11 Nov 2021 Status changed from recruiting to completed.
- 29 Apr 2020 Planned End Date changed from 18 Feb 2020 to 28 Feb 2021.
- 29 Apr 2020 Planned primary completion date changed from 7 Jan 2020 to 30 Nov 2020.